Radiofrequency ablation (RFA) is a well-established treatment for several benign, premalignant, and malignant disorders. Although the role of RFA has been clearly defined, new indications for luminal and extraluminal applications of endoscopic RFA-directed therapies have emerged. RFA has recently produced promising results in patients with a variety of gastrointestinal and hepatopancreatobiliary pathologies. For example, endoscopic RFA has been used to treat patients with gastric antral vascular ectasia, chronic radiation proctitis, malignant biliary strictures, and ampullary adenomas with intraductal extension. Furthermore, endoscopic ultrasound-guided RFA appears to be an effective, minimally invasive treatment for ablation of solid and cystic lesions-particularly in the pancreas. We review the newer indications for RFA and discuss potential limitations of endoscopic RFA.
W ithin the field of gastroenterology, radiofrequency ablation (RFA) is a well-established modality for the treatment of a variety of benign, premalignant, and malignant conditions. 1 Endoscopic RFA has been shown to achieve mucosal ablation in several types of benign hemorrhagic gastrointestinal diseases. In addition, endoscopic RFA has been validated as an approved treatment for premalignant conditions as seen in patients with Barrett's esophagus with dysplasia, in whom it has been shown to achieve highly effective and durable results. [1] [2] [3] [4] [5] RFA for the treatment of esophageal metaplasia and dysplasia, although similar to electrocautery, initially was established for and patented in a porcine and human model by Ganz et al 6 in 1999. The device involved a balloon-based, bipolar radiofrequency system that created a circumferential, thin-layer, epithelial ablation zone within the esophagus. Still today, the technique involves highfrequency alternating electrical current delivered locally to tissue or mucosa. This localized controlled heating results in targeted destruction and thermal coagulative necrosis.
Although the role of RFA has been clearly defined in the management of Barrett's esophagus, new indications for endoscopic RFA-directed treatment have emerged with the promise of improving the management of patients who do not have many options at the present time. 5, 7, 8 Endoscopic RFA possesses the potential for expanded use in a multitude of gastrointestinal and hepatopancreatobiliary diseases. This review highlights these newer luminal and extraluminal indications and reviews the existing literature to support an emerging role of endoscopic RFA for these indications.
Gastric Antral Vascular Ectasia
Classically detailed as having a watermelon or honeycomb appearance, gastric antral vascular ectasia (GAVE) is a collection of dilated tortuous vessels first described by Rider et al 9 in 1953. 10 Pharmacotherapy with octreotide, tranexamic acid, and estrogen-progesterone hormonal therapy typically is ineffective. [11] [12] [13] Endoscopic therapy is presently the preferred treatment modality with options that include nonthermal and thermal approaches. At this time, a thermal approach with argon plasma coagulation (APC) is considered the first-line endoscopic treatment of choice.
14 This is in large part because APC is associated with a low complication rate and is cost effective. Despite this, studies have shown mixed success rates to date, with approximately two thirds of GAVE patients remaining transfusion-dependent. 15 Recently, RFA has emerged as a viable alternative endoscopic modality for GAVE with many devices available to gastroenterologists ( Table 1 ). The procedure involves mounting the RFA electrode array on an endoscope with the device advanced to the pylorus. 16, 17 After insertion, the endoscope is deflected to place the articulated electrode against the mucosal area of desired treatment. Typically, 2 to 4 consecutive pulses of energy are delivered (at a preset and automated energy density dose of 12 J/cm 2 ) in the same area without scraping off to promote optimal hemostasis. The goal of each session is to perform circumferential ablation of the desired lesions and eradicate at least 90% of abnormal gastric mucosa.
In 2008, Gross et al 18 designed a pilot study to explore RFA in 6 patients, 5 of whom (83.33%) were observed to no longer be transfusion-dependent. Several years later, McGorisk et al 17 revived this procedure and reported on the efficacy and safety of RFA for patients with GAVE. This was an open-label, prospective cohort of 21 patients who underwent at least 1 RFA session with ablation of GAVE lesions. RFA was performed using the HALO-90 ULTRA ablation catheter (Covidien, GI Solutions, Sunnyvale, CA) delivered at high-power density (40 W/cm 2 ) at a preset and automated energy density dose of 12 J/cm 2 . On follow-up evaluation 6 months after ablation, 18 of 21 patients (86%) became transfusionindependent with a mean hemoglobin level increasing from 7.8 to 10.2 g/dL in responders. Pre-and post-RFA treatment for GAVE is shown in Figure 1 . 17 A subsequent retrospective study by Dray et al 16 found similar results. In this study of 24 patients, 23 of whom were transfusion-dependent, the mean number of red cell units transfused decreased in all transfusiondependent patients (mean, 10.6 AE 12.1 before RFA compared with 2.5 AE 5.9 at 6 mo after RFA; P < .001). A more recent case series of 7 patients by Jana et al 19 found endoscopic RFA to be an effective alternative to APC for the treatment of GAVE in patients refractory to previous endoscopic therapy. Although a limited number of patients were enrolled and a median number of 2 RFA sessions produced a modest improvement in hemoglobin level after the procedure, 71% of patients (5 of 7) were no longer transfusion-dependent, with no immediate complications reported. Drawing on these data, RFA appears to be an attractive endoscopic option for gastroenterologists because the modality allows for larger mucosal surfaces to be treated when compared with APC. 17, 18, 20 Although few studies have sought to compare RFA directly with APC, our recent meta-analysis reported clinical and endoscopic success for RFA to be significantly higher compared with APC. 21 In addition, endoscopic RFA required fewer treatment sessions for clinical or endoscopic resolution as compared with APC (a difference of 1.27 endoscopies per successfully treated patient) ( Table 2) . [16] [17] [18] [19] [21] [22] [23] Furthermore, both APC and RFA achieved similar increases in mean hemoglobin level; the number of complications also was similar across the 2 modalities. Although only a limited number of studies have been performed to evaluate RFA for the treatment of GAVE (6 RFA studies were included in this meta-analysis), likely in part owing to the novelty of the procedure for this pathology, available evidence suggests that RFA may possess a better efficacy and tolerability compared with APC. 21 Although future controlled trials and comparator studies are needed to compare treatment efficacy, long-term durability, cost effectiveness, and safety between these interventions, the use of endoscopic RFA for the treatment of GAVE may become standard of care.
Chronic Radiation Proctitis
Chronic radiation proctitis (CRP) may occur in as many as 20% of patients who have received pelvic radiation. 24 Again, just as was the case for GAVE, APC presently provides a cost-effective endoscopic modality for CRP traditionally used by gastroenterologists. In fact, the American Society for Gastrointestinal Endoscopy currently considers APC for hemostasis best suited for superficial vascular lesions, such as those seen in GAVE and CRP. 25 Despite this recommendation, there remains insufficient comparative data to truly assess the performance of APC in relation to other modalities for CRP. Perhaps more importantly, current ablative therapies, APC included, have a high complication rate of up to 47%, with the potential for deep tissue injury leading to ulcerations, perforations, and fistulae in patients with CRP. 24 Given this unacceptably high adverse event rate coupled with a lack of comparative data, Zhou et al 26 explored the feasibility of RFA as a potential alternative modality in a small case series of 3 patients with refractory CRP. Hemostasis was achieved in all patients with 1 to 2 RFA sessions, and no ulcerations or stricturing was observed on follow-up evaluation 19 months after the procedure. Additional data from a retrospective series of 4 patients by Pigo et al 27 showed endoscopic RFA to be an efficacious procedure achieving complete control of patient symptoms. All patients were no longer transfusion-dependent after the procedure, and no major complications were noted, although 2 patients (50%) developed limited, post-treatment superficial ulcers that healed within 2 to 3 weeks.
Recently, a retrospective multicenter analysis of prospectively collected data was performed involving RFA for the treatment of CRP. 28 A total of 39 CRP patients were enrolled, with the study's primary end point being complete resolution of rectal bleeding. To achieve ablation of CRP, the HALO-90 ablation catheter was mounted on the endoscope in the 6 o'clock position with an energy setting of 12 J/cm 2 . Generally, 2 applications of the RFA were performed per site, in the retroflexed position, to best visualize the dentate line. Ablations were placed approximately 1 mm proximal to the dentate line to avoid the sensory tissues of the anal mucosa, and treatments were limited to less than 270 of circumference during any single session to minimize the potential risk of stricture formation. Re-treatment was performed 12 to 16 weeks after the first treatment only if rectal bleeding persisted.
Importantly, this study enrolled patients regardless of previous therapy, with 59% of patients having undergone previous medical treatment and 36% with a prior endoscopic therapy (n ¼ 13 patients with failed APC, n ¼ 1 patient with prior cryoablation). Impressively, endoscopic RFA achieved complete cessation of rectal bleeding in all patients during a mean follow-up period of 28 months (range, 7-53 mo). The mean hemoglobin levels before and after the procedure increased from 11.8 to 13.5 g/dL, respectively, with a mean number of 1.49 RFA sessions required and a mean interval of 18 weeks between sessions. In addition, 92% of patients no longer required transfusions and 82% of patients discontinued iron therapy. Most importantly, no major adverse events occurred. Figure 2 contains followup endoscopic images that show gradual healing and complete re-epithelialization in patients with CRP after treatment with RFA. 28 Similar results were reported by Dray et al 29 in another multicenter retrospective study of 17 patients. Six of the 17 patients received previous treatment with APC. With a median of 2 RFA sessions (range, 1-4 sessions), the hemoglobin concentration increased in all 17 patients (preprocedure mean, 8.3 AE 2.8 g/dL; postprocedure mean, 11.3 AE 2.2 g/dL; P < .01). Two patients developed rectal ulcerations with no local symptoms and no serious adverse events occurred. During the 6 months after RFA, 53% of patients who were transfusiondependent (9 of 13 patients total) no longer required transfusion therapy. Table 3 includes important baseline characteristics of studies evaluating RFA for the treatment of CRP. [26] [27] [28] [29] [30] Based on these studies, endoscopic RFA appears to a promising modality capable of providing a first-or second-line treatment option for patients with CRP.
Malignant Biliary Strictures
Biliary strictures continue to present a diagnostic and therapeutic dilemma for biliary endoscopists. Malignant biliary obstruction is caused most commonly by cholangiocarcinoma or pancreatic adenocarcinoma. Traditionally used as a palliative measure in patients with nonresectable or borderline resectable biliary disease, self-expanding metal stents (SEMS) have been shown to be superior to plastic stents in regard to patency and decreased risk of stent migration with improved tissue engraftment. Despite SEMS providing a superior alternative to plastic stents, the high occlusion rate limits the effectiveness of SEMS. With occlusion rates of up to 40% within 6 months of insertion, adjunctive endoscopic modalities have been proposed. 31, 32 Although endoscopically delivered photodynamic therapy (PDT) has shown improved stent patency, biliary drainage, mortality, and quality of life, the associated phototoxicity requiring patients to avoid direct sunlight limits PDT's application. [33] [34] [35] [36] [37] [38] The other modality added to reduce SEMS dysfunction involves intraductal RFA-a procedure that entails using a biliary catheter device, via an endoscopic or percutaneous approach. The RFA catheter (Habib EndoHPB; EMcision Ltd, London, UK) is a single-use, disposable, bipolar device that is suitable for endoluminal delivery of RFA into the biliary tree over a (Figure 3 ). It consists of an 8F (2.6-mm) catheter with a 180-cm working length that can be deployed through endoscope working channels of at least 3.2 mm in diameter. 39 This modality allows for ablation of the tumors within the bile duct lumen for the maintenance of biliary drainage. Endobiliary RFA additionally acts directly on the local tumor and can be an adjunct to endoscopic palliation in that it has been suggested to increase SEMS patency and potentially improve survival. 39 A recent retrospective German study by Schimdt et al 40 sought to compare the efficacy and safety of intraductal RFA with PDT for the treatment of hilar cholangiocarcinoma. Fourteen patients treated with biliary RFA (n ¼ 31 sessions total) were compared with a historical control of 20 patients treated with PDT (n ¼ 66 sessions total). A total of 14 patients enrolled in the biliary RFA cohort showed a significant decrease in their 2-week postprocedure bilirubin level, with no significant change in the PDT cohort of 20 patients (P ¼ .046 and P ¼ .67, respectively) ( Figure 4) . 40 In addition, stent patency also was improved in the intraductal RFA group with a rate of premature stent replacement (defined as replacement < 3 mo, PDT 65% vs RFA 29%; P < .001) that was significantly higher in the PDT cohort, with a trend toward more adverse events in the PDT than in the RFA group (40% vs 21%, respectively; P ¼ .277). These results, combined with a potential lower procedureassociated complication rate, may suggest an increased role for intraductal RFA as a therapeutic alternative to PDT for palliative treatment of malignant biliary obstruction.
Further attempts to compare RFA and PDT have been performed, although a truly comparative trial is lacking. A retrospective cohort study by Strand et al 33 Figure 5) . 33 Although intraductal RFA may be an emerging modality, future prospective controlled trials are needed to determine which palliative option increases the odds of short-and long-term survival. 41 To date, numerous additional case series have evaluated the use of endoscopic biliary RFA for the treatment of malignant biliary strictures. 33, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] Of these included studies, Figueroa-Barojas et al 47 showed encouraging clinical data reporting pre-and post-RFA luminal diameter of the stricture to have significant improvement (1.7 mm; range, 0.5-3.4 vs 5.2 mm; range, 2.6-9, respectively). Additional studies have described similarly impressive results, with 1 study reporting a pooled mean increase in stricture diameter of 3.7 mm after RFA therapy. 39, 42, 43 However, despite the dramatic improvement in post-RFA luminal diameter, this modality is not without complications (Table 4) . 46, 49, 53, 54 Adverse events may occur in 10% to 62% of patients ranging from selflimited abdominal pain (reported in up to 50% patients), cholangitis, acute cholecystitis, and major hemobilia from hepatic artery pseudoaneurysm. 39, 54 Therefore, it is important for the biliary endoscopist to be aware of these adverse events. Multiple factors may account for such a wide variability in adverse events including differences in etiology, location, thickness of stricture and duct wall, proximity of hepatic artery branches to the bile duct, variability in energy settings, and type of biliary stents placed after RFA, and perhaps surgeon technique and experience.
In addition, the notion that RFA may improve stent patency has been debated. 54 Although many studies have suggested that RFA may decrease the rate of SEMS occlusion, 2 studies that aimed to evaluate this theory showed statistically insignificant results compared with controls. 55, 56 However, a recent retrospective study by Kadayifci et al 57 showed that mean stent patency time was significantly longer in the RFA group. Patients treated with endoscopic RFA using a Habib Endoprobe for the treatment of occluded SEMS (n ¼ 25) were compared with a control group treated with plastic stent insertion (n ¼ 25). The stent patency rate at 90 days and the mean stent patency time during the 5-year study period were significant higher for patients who underwent RFA (rate, 56% vs 24%; P ¼ .04; time, 119.5 vs 65.3 d; P ¼ .03). Another study by Yang et al 58 examined survival time and stent patency in patients with unresectable extrahepatic cholangiocarcinoma. Twenty-nine patients underwent RFA and stenting whereas 30 patients underwent stent placement alone. The mean overall survival and stent patency was significantly longer in the RFA and stent group compared with the stent alone group (13.8 vs 3.5 mo; P < .002; and 6.9 vs 3.5 mo; P ¼ .02; respectively). Importantly, no significant difference was noted in the incidence of postprocedural complications between the RFA group and stent cohort (6.9% vs 10%, respectively; P ¼ .67).
Recently, a systematic review and meta-analysis was performed to evaluate the efficacy and safety of biliary stenting with RFA compared with stenting alone in patients with malignant biliary strictures. 59 This meta-analysis included 8 studies (n ¼ 416) with a similar method of biliary RFA across all studies. Patient demographics, number with pancreatitis cancer, and mean length of biliary stricture was similar between the 2 groups. Overall, stent patency was improved significantly in biliary stenting with RFA patients compared with stenting alone (pooled weighted mean difference, 45.07 d), with no significant difference seen between the 2 cohorts in regard to risk of cholangitis, acute cholecystitis, pancreatitis, and hemobilia. Furthermore, a pooled survival analysis showed improved survival in patients treated with RFA (hazard ratio, 1.49; P < .001) (Figure 6) . 59 An additional meta-analysis by Zheng et al 60 found similar results including a significant increase in stricture diameter and survival time, suggesting that endoscopic RFA may be preferable in the management of malignant biliary obstruction. 60 Although prospective randomized trials are needed to further validate these findings, it appears that endoscopic RFA may improve stent 
Intraductal Extension of Ampullary Adenoma
Ampullary adenomas often are treated by endoscopic papillectomy. However, endoscopic management of ampullary adenomas extending into the common bile duct or pancreatic duct remains challenging. Intraductal extension typically has been considered a contraindication to endoscopic management and, as such, patients have been referred for surgical management. However, a pancreaticoduodenectomy or a Whipple procedure has high associated morbidity and mortality, thus making endoscopic management an attractive alternative. Recently, a retrospective multicenter study evaluated the feasibility, safety, and efficacy of endoscopic RFA for ampullary neoplasms with intraductal extension. 61 In this study, a total of 14 patients with adenoma extension into the common bile duct (13 AE 7 mm; n ¼ 14) and pancreatic duct (7 AE 2 mm; n ¼ 3) were treated with a RFA catheter. With treatment failure documented and persistent tumor invasion shown histologically, these patients underwent a median of 1 RFA session (range, 1-5 sessions). At a median follow-up period of 16 months after RFA, complete intraductal ablation was achieved in 91.6% of patients. Adverse events occurred in 43% and included ductal strictures (n ¼ 5) and a retroduodenal abscess (n ¼ 1), all of which were successfully treated endoscopically. 62 Another small case series of 4 patients by Suarez et al 63 found similar results, with 3 patients achieving complete eradication of the intraductal adenoma extension with no immediate adverse events noted during the short follow-up period. In summation, these studies, although small in number, show RFA to be a relatively safe and effective modality for the treatment of ampullary neoplasms with intraductal extension. Although more studies are needed before this can be implemented routinely, early data suggest an expanded role for endoscopic RFA in future clinical practice.
Early Data on Endoscopic UltrasoundGuided Radiofrequency Ablation
Another potential avenue for endoscopic RFA is in regard to the modality's use with endoscopic ultrasound (EUS). Although the clinical application of EUS-guided RFA is not as well established as the previously discussed indications, with very few studies on the topic, the combined use of EUS with ablation holds promise. EUS-guided RFA offers the best combination of real-time visualization and precise localization coupled with a minimally invasive strategy to achieve selective ablation of a variety of lesions previously inaccessible or difficult to access via percutaneous routes. 64 At present, EUS-guided RFA has been shown to be effective for targeting lesions within the liver, pancreas, lymph node, and for ablation of celiac ganglia for pain control in pancreatic carcinoma. Although these indications remain experimental and currently performed only at centers with expertise under predetermined protocols, there are emerging data supporting a potential role for EUS-guided RFA in select patients.
EUS-guided liver RFA first was shown experimentally by Varadarajulu et al 65 in 2009, using a 19-gauge echogenic, umbrella-shaped, monopolar electrode in 5 porcine models. In this study, RFA achieved discrete, well-demarcated, 2.6-cm spherical focus of coagulation necrosis with tissue ablation within 7 minutes. On histopathology, all pigs showed complete coagulative necrosis without damage to the surrounding liver parenchyma or vasculature. Despite these findings, translation of these impressive results to human studies has been limited. 66 Ex vivo data regarding the ideal power setting or the duration of ablation needed to effectively treat hepatic masses has been another limiting factor in the expanded use of EUS-guided RFA. Use of the Habib RFA catheter (Habib, EndoHPB, EUS; EMcision Ltd) in a recent study, again in an animal model, showed that maximal zones of injury were achieved using an ablation power of 10 W for a duration of 90 seconds. 67 Higher power settings (ie, 15 W, 20 W, and 50 W) were noted to paradoxically achieve a smaller radial length or small ablation zones. This has been attributed to rapid charring of the hepatic tissue around the small-caliber RFA wire at high power with subsequently increased impedance, thus interfering with the conduction of the current with no further spread of ablation. Given these data, future studies may highlight an expanded role for EUS-guided RFA for treatment of primary and secondary hepatic masses; however, translation to human models is lacking at this time.
With regards to pancreatic lesions, Goldberg et al 68 first conducted EUS-guided RFA on 16 porcine models and showed discrete histologic progression of coagulation necrosis followed by fibrotic capsule contraction. Although pancreatic RFA has a high risk of complication owing to increased sensitivity of pancreatic tissue and proximity to vascular and biliary structures, early animal studies have shown impressive results. 68, 69 An early human study by Pai et al 70 relieved many concerns by showing no immediate or early major postprocedural complications. In this prospective multicenter trial using an innovative monopolar RFA probe (1.2-mm Habib EUS-RFA catheter; EMcision Ltd), 8 patients (n ¼ 6 with pancreatic cystic neoplasms; n ¼ 2 with neuroendocrine tumors) were treated successfully with EUS RFA. The mean size of these lesions was 36.5 AE 17.9 mm and 27.5 AE 17.7 mm for cystic lesions and neuroendocrine tumors, respectively. At a follow-up period of 3 to 6 months, RFA achieved complete resolution in 2 cystic lesions, with a 48.4% reduction noted in 3 remaining patients. A change in vascularity and central necrosis was observed in both neuroendocrine tumor cases after EUS RFA. Importantly, no serious adverse events were reported among patients with cystic lesions and neuroendocrine tumors. A more recent study by Song et al 71 used an 18-gauge RFA electrode inserted into the pancreatic mass with increased blood flow after RFA. This study used a RFA generator activated to deliver 20 to 50 W ablation power for 10 seconds and was performed successfully in all 6 patients included in the study. The mean diameter of pancreatic masses was 3.8 cm (range, 3-9 cm), with the head (n ¼ 4) and body (n ¼ 2) of the pancreas tumors included. Figure 7 highlights significant improvement in the size of the pancreatic head cancer after treatment with RFA. 71 Again, no adverse events such as pancreatitis or bleeding occurred.
Additional studies by Lakhtakia et al 72 and Arcidiacono et al 73 have shown the feasibility and safety of EUS-guided pancreatic RFA for pancreatic insulinoma and locally advanced pancreatic cancer, respectively. Lakhtakia et al 72 used a prototype 19-gauge needle electrode, generator, and internal cooling system in 3 patients with nonsurgical pancreatic insulinomas and achieved rapid symptom relief with patients remaining symptom free at the 12-month follow-up evaluation (Figure 8) . 72 In patients with local progression of advanced pancreatic adenocarcinoma status-post neoadjuvant therapy, Arcidiacono et al 73 achieved EUS-guided cryotherm probe (ERBE Elektromedizin GmbH, Tubingen, Germany) ablation in 72.8% (16 of 22 patients). The median post-RFA ablation survival time was 6 months, with tumor size appearing smaller on follow-up computed tomography imaging. These innovative RFA catheters have allowed endoscopists to deliver RFAdirected treatment to patients with lesions previously inaccessible through surgical approaches.
Lymph node ablation with novel EUS-guided RFA also has been performed in animal models, again with positive results. Sethi et al 74 analyzed the modality on 18 porcine mediastinal lymph nodes with a mean node length of 2.08 cm. By using a prototype RFA probe (EMcision Ltd) with a 0.01-mm diameter and a 3-cm ablation tip, the mean length and diameter of necrosis achieved was 9.8 mm and 5.5 mm, respectively (mean, 17.6% of lymph node area ablated). Importantly, no complications occurred with the procedure. With these data and prototype EUS-compatible RFA probe, EUS-RFA lymph node ablation may have the potential for future translation into human studies for management of patients with malignant/metastatic lymph nodes. 74 Specifically with regard to pancreatic cancer, EUS-guided celiac ganglion RFA for pain control has been shown in a single-patient case report. 75 Significant improvement in pain with a reduction in narcotic intake was reported after EUSguided celiac ganglion RFA using the Habib RFA probe through a 19G EUS needle (Figure 9) . Identification of the celiac ganglia with EUS has enhanced the efficacy and safety of the celiac plexus nerve block by enabling direct visualization and precise ablation. 76 Whether using RFA over the current standard chemical ablation with EUS-guided celiac neurolysis using alcohol has any clinical advantages needs to be evaluated. More data are needed to establish the safety, long-term durability, and cost effectiveness of EUS-guided celiac RFA neurolysis.
Conclusions
At present, endoscopic RFA is well validated for the treatment of dysplastic Barrett's; however, the use of this endoscopic modality has been expanded to include several other difficult-to-treat diseases (Table 5 ). These newer indications may provide definitive treatment, palliation, or alternative therapies for a wide variety of gastrointestinal and hepatopancreatobiliary pathologies. Despite being a feasible and safe modality, high RFAassociated costs may limit these expanded applications. Still, with more widespread use and improved implementation, the cost of this innovative modality likely will decrease, making this a more affordable and practical option. Similar to any innovative technique, future direct comparative trials and cost-effectiveness analyses are needed, along with long-term follow-up data to establish the long-term safety and efficacy of endoscopic RFA for these newer indications. Until such time, based on the limited data as presented earlier, endoscopic RFA appears to be a viable, innovative, and emerging modality with expanding indications. 
